Cell-free DNA as a prognostic marker in stage I non-small-cell lung cancer patients undergoing stereotactic body radiotherapy

Maria Teresa Bortolin, Rosamaria Tedeschi, Ettore Bidoli, Carlo Furlan, Giancarlo Basaglia, Emilio Minatel, Carlo Gobitti, Giovanni Franchin, Marco Trovò, Paolo De Paoli

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To evaluate whether plasma cell-free DNA (cfDNA) was related to clinical outcome in inoperable stage I non-small cell lung cancer (NSCLC) patients undergoing stereotactic body radiotherapy (SBRT).Materials and methods: Plasma cfDNA was assessed at baseline, before the last day and 45 days after the end of SBRT, in 22 NSCLC patients. Twenty-two healthy controls were also evaluated.Results: Plasma cfDNA was higher in patients than in controls. An association with unfavourable disease-free survival was found for continuous baseline cfDNA increments (HR = 5.9, 95%CI: 1.7-19.8, p = 0.04).Conclusion: Plasma cfDNA may be a promising prognostic biomarker in high-risk NSCLC patients.

Original languageEnglish
Pages (from-to)422-428
Number of pages7
JournalBiomarkers
Volume20
Issue number6-7
DOIs
Publication statusPublished - Oct 3 2015

Keywords

  • Biomarker
  • cell-free DNA
  • early stage
  • lung cancer
  • stereotactic body radiotherapy

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Health, Toxicology and Mutagenesis

Fingerprint

Dive into the research topics of 'Cell-free DNA as a prognostic marker in stage I non-small-cell lung cancer patients undergoing stereotactic body radiotherapy'. Together they form a unique fingerprint.

Cite this